> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tissues Office Renamed Office of Therapeutic Products
- URL: https://www.fdaweb.com/tissues-office-renamed-office-of-therapeutic-products/
- Published: 2022-09-27T12:00:00.000Z
- Updated: 2026-09-14T18:00:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152824

*Federal Register* notice: CBER’s Office of Tissues and Advanced Therapies has modified its organizational structures effective 9/16 to rename it the Office of Therapeutic Products (OTP) and elevate it to a super office to manage its program at a macro level and to better position the Center to address the changing public health landscape. The Center is anticipating increased workloads in the cell and gene therapy space and its related Regenerative Medicine Advanced Therapy program. The Center says the structural changes will improve functional alignment, increase review capabilities, and enhance expertise on these products. “Additional supervisory positions will not only help to address this increased workload but will also provide advancement opportunities to facilitate recruitment and retention of highly qualified staff,” the notice says. “The proposal creates flexibility and capacity for future growth in Full-Time Employees (FTEs) and workload, avoiding the need for continual reorganizations.” The reorganization is also intended to support OTP’s focus on commitments, including those negotiated with industry in the upcoming user fee reauthorization. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-20997.pdf?ref=fdaweb.com).